Inventiva Publishes Promising Results on Lanifibranor for Liver Disease

Inventiva has announced the publication of its study results in the Journal of Hepatology Reports. The research focuses on the effects of lanifibranor on liver sinusoidal endothelial cells (LSEC) in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The study is part of the Phase 2b NATIVE clinical trial.

The results indicate a notable improvement in LSEC capillarization in patients with MASH. Additionally, preclinical models showed lanifibranor's potential to normalize portal pressure and intrahepatic vascular resistance, pointing to its comprehensive therapeutic potential. Comparison with single PPAR agonists suggests superior effects of lanifibranor, enhancing its promise as a treatment option.

This publication reinforces lanifibranor's potential role in managing liver diseases and preventing progression to cirrhosis.